AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:

* * *

Late-Breaking HARMONi-2 Analysis Shows Ivonescimab Significantly Improves Overall Survival Versus Pembrolizumab in PD-L1-Positive Advanced NSCLC

*

(SEOUL, Republic of Korea -September 13th at 10:45 a.m. Korea Standard Time) -Ivonescimab significantly prolonged overall survival compared with pembro . . .

Click here for more information about our products